Mesenchymal Stem Cell Applications in Graft Versus Host Disease

Öz

Allogeneic hematopoietic stem cell transplantation stands as a promising cure for a variety of diseases. However, the potential of acute or chronic graft-versus-host disease (GvHD), which leads to significant morbidity and mortality, remains a cause for concern. GvHD occurs due to the complex interactions of immune cells from the graft and the host cells. Despite the existence of prophylactic treatments, GvHD may still occur, and the resistance to conventional therapies necessitates novel approaches and treatments. Mesenchymal stem cells, which are pluripotent stem cells capable of self-renewal and multilineage differentiation, have gained attention for their low immunogenicity and ability to be sourced from various origins. They have shown promise as therapeutic tools for the cell-based treatment of inflammatory, immune-mediated, and degenerative diseases owing to their remarkable abilities in immunomodulation, immunosuppression, and tissue regeneration. In GvHD, MSCs have demonstrated therapeutic potential through paracrine activity and organelle transfer via nanotubes, microvesicles, or exosomes. The emergence of MSCs as a treatment for severe steroid-resistant GvHD gained attention in the early 2000s. While initial studies have demonstrated encouraging results in the use of MSCs for the prevention of GvHD, there is still a need for further investigation. Therefore, in this current review, we aim to delve deeper into MSC’s features and their clinical applications in the case of GvHD treatment.

Anahtar Kelimeler

• Mesenchymal stem cell
• Hematopoietic stem cell
• Immunomodulation
• Stem cell transplantation
• Graft-versus-host disease

Graft Versus Host Hastalığı'nda Mezenkimal Kök Hücre Uygulamaları

Öz

Allojenik hematopoetik kök hücre transplantasyonu, pek çok hastalık için umut verici bir tedavi yöntemidir. Ancak tedavinin bir komplikasyonu olabilen akut veya kronik greft-versus-host hastalığı (GvHH) mortalite ve morbidite riskini önemli ölçüde artırabilmektedir. GvHH, donörden gelen bağışıklık hücreleri ile konak hücreleri arasındaki uygunsuz immün yanıttan kaynaklanmaktadır. Profilaktik tedavilerin varlığına rağmen, GvHH hala görülebilmekte olup konvansiyonel tedavilere direnç, yeni tedavi çalışmalarının gerekliliğini ortaya koymaktadır. Mezenkimal kök hücreler (MKH), kendini yenileyebilme, farklı doku hücrelerine farklılaşma, düşük immunojenite özelliklerine sahip olup çeşitli dokulardan elde edilebilirler. İmmünomodülasyon, immünsüpresyon ve doku rejenerasyonu özelliklerinden dolayı, inflamatuar, immün aracılı, dejeneratif hastalıkların tedavisinde umut vaat etmektedirler. GvHH'de, MKH’ler, parakrin aktivite ve nanotüpler, mikroveziküller veya eksozomlar yoluyla terapötik potansiyel gösterebilmektedirler. Steroid tedavisine dirençli GvHH'nin tedavisi için MKH’ler 2000'lerin başında kullanılmaya başlanmış olup, yapılan çalışmalar MKH’lerin etkili bir teröpötik araç olduğunu göstermiştir, ancak daha fazla araştırmaya ihtiyaç duyulmaktadır. Bu derlemede MKH'lerin özelliklerini ve GvHH tedavisindeki klinik uygulamalarını incelemeyi amaçladık.

Anahtar Kelimeler

• mezenkimal kök hücre
• graft versus host hastalığı
• kök hücre nakli
• hematopoetik kök hücre
• immunmodülasyon

Kaynakça

1. Garnett C, Apperley JF, Pavlů J. Treatment and management of graft-versus-host disease: improving response and survival. Ther Adv Hematol 2013;4:366-78.
2. Phelan R, Chen M, Bupp C, Bolon Y-T, Broglie L, Brunner-Grady J, et al. Updated trends in hematopoietic cell transplantation in the United States with an additional focus on adolescent and young adult transplantation activity and outcomes. Transplant Cell Ther 2022;28:409. e1-. e10.
3. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005;11:945-56.
4. Zeiser R, Blazar BR. Acute graft-versus-host disease—biologic process, prevention, and therapy. N Engl J Med 2017;377:2167-79.
5. Ullah I, Subbarao RB, Rho GJ. Human mesenchymal stem cells-current trends and future prospective. Biosci Rep 2015;35:e00191.
6. Shafeghat Z, Dorfaki M, Dehrouyeh S, Arab FL, Roozbehani M, Falak R, et al. Mesenchymal stem cell-derived exosomes for managing graft-versus-host disease: An updated view. Transpl Immunol 2023:101957.
7. Prasad VK, Lucas KG, Kleiner GI, Talano JAM, Jacobsohn D, Broadwater G, et al. Efficacy and safety of ex vivo cultured adult human mesenchymal stem cells (Prochymal™) in pediatric patients with severe refractory acute graft-versus-host disease in a compassionate use study. Biol Blood Marrow Transplant 2011;17:534-41.
8. Zheng Q, Zhang S, Guo W-Z, Li X-K. The unique immunomodulatory properties of MSC-derived exosomes in organ transplantation. Front Immunol 2021;12:659621.

9. Lai P, Chen X, Guo L, Wang Y, Liu X, Liu Y, et al. A potent immunomodulatory role of exosomes derived from mesenchymal stromal cells in preventing cGVHD. J Hematol Oncol 2018;11:1-15.
10. Li K-L, Li J-Y, Xie G-L, Ma X-Y. Exosomes released from human bone marrow–derived mesenchymal stem cell attenuate acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation in mice. Front Cell Dev Biol 2021;9:617589.
11. Crippa S, Santi L, Berti M, De Ponti G, Bernardo ME. Role of ex vivo expanded mesenchymal stromal cells in determining hematopoietic stem cell transplantation outcome. Front Cell Dev Biol 2021;9:663316.
12. Galderisi U, Peluso G, Di Bernardo G. Clinical trials based on mesenchymal stromal cells are exponentially increasing: where are we in recent years? Stem Cell Rev Rep 2022;18:23-36.
13. Introna M, Golay J. Tolerance to bone marrow transplantation: do mesenchymal stromal cells still have a future for acute or chronic GvHD? Front Immunol 2020;11:609063.
14. Kostareva I, Kirgizov K, Machneva E, Ustyuzhanina N, Nifantiev N, Skvortsova Y, et al. Novel and Promising Strategies for Therapy of Post-Transplant Chronic GVHD. Pharmaceuticals 2022;15:1100.
15. Li Z, Rubinstein SM, Thota R, Savani M, Brissot E, Shaw BE, et al. Immune-mediated complications after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2016;22:1368-75.
16. Saidu NEB, Bonini C, Dickinson A, Grce M, Inngjerdingen M, Koehl U, et al. New approaches for the treatment of chronic graft-versus-host disease: current status and future directions. Front Immunol 2020;11:578314.
17. Zeiser R, Marks R, Bertz H, Finke J. Immunopathogenesis of acute graft-versus-host disease: implications for novel preventive and therapeutic strategies. Ann Hematol 2004;83:551-65.
18. DeFilipp Z, Couriel DR, Lazaryan A, Bhatt VR, Buxbaum NP, Alousi AM, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: III. The 2020 treatment of chronic GVHD report. Transplant Cell Ther 2021;27:729-37.
19. Spees JL, Lee RH, Gregory CA. Mechanisms of mesenchymal stem/stromal cell function. Stem Cell Res Ther 2016;7:125.
20. Wei X, Yang X, Han Z-p, Qu F-f, Shao L, Shi Y-f. Mesenchymal stem cells: a new trend for cell therapy. Acta Pharmacol Sin 2013;34:747-54.
21. Chen C. From mesenchymal stem cell therapy to discovery of drug therapy for systemic sclerosis. University of Southern California, ProQuest Dissertations Publishing 2014; 3628136.
22. Saeedi P, Halabian R, Fooladi AAI. A revealing review of mesenchymal stem cells therapy, clinical perspectives and Modification strategies. Stem Cell Investig 2019;6:34.
23. Wannemuehler TJ, Manukyan MC, Brewster BD, Rouch J, Poynter JA, Wang Y, et al. Advances in mesenchymal stem cell research in sepsis. J Surg Res 2012;173:113-26.
24. Galipeau J, Sensébé L. Mesenchymal stromal cells: clinical challenges and therapeutic opportunities. Cell stem cell 2018;22:824-33.
25. Harrell CR, Jovicic N, Djonov V, Arsenijevic N, Volarevic V. Mesenchymal stem cell-derived exosomes and other extracellular vesicles as new remedies in the therapy of inflammatory diseases. Cells 2019;8:1605.
26. Hirvonen T. Glycan binding proteins in therapeutic mesenchymal stem cell research. Helsinki, University of Helsinki, Finland 2014.
27. Kusadasi N, Groeneveld AJ. A perspective on mesenchymal stromal cell transplantation in the treatment of sepsis. Shock. 2013;40:352-7.
28. Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P, et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002;99:3838-43.
29. Rasmusson I, Ringdén O, Sundberg B, Le Blanc K. Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation 2003;76:1208-13.
30. Burnham AJ, Daley-Bauer LP, Horwitz EM. Mesenchymal stromal cells in hematopoietic cell transplantation. Blood Adv 2020;4:5877-87.
31. Cooke KR, Luznik L, Sarantopoulos S, Hakim FT, Jagasia M, Fowler DH, et al. The biology of chronic graft-versus-host disease: a task force report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant 2017;23:211-34.
32. Corcione A, Benvenuto F, Ferretti E, Giunti D, Cappiello V, Cazzanti F, et al. Human mesenchymal stem cells modulate B-cell functions. Blood 2006;107:367-72.
33. Weiss ARR, Dahlke MH. Immunomodulation by mesenchymal stem cells (MSCs): mechanisms of action of living, apoptotic, and dead MSCs. Front Immunol 2019;10:1191.
34. Martin I, Galipeau J, Kessler C, Le Blanc K, Dazzi F. Challenges for mesenchymal stromal cell therapies. Sci Transl Med 2019;11:eaat2189.
35. Terness P, Bauer TM, Röse L, Dufter C, Watzlik A, Simon H, et al. Inhibition of allogeneic T cell proliferation by indoleamine 2, 3-dioxygenase–expressing dendritic cells: mediation of suppression by tryptophan metabolites. J Exp Med 2002;196:447-57.
36. Fu Y, Sui B, Xiang L, Yan X, Wu D, Shi S, et al. Emerging understanding of apoptosis in mediating mesenchymal stem cell therapy. Cell Death Dis 2021;12:596.
37. Galleu A, Riffo-Vasquez Y, Trento C, Lomas C, Dolcetti L, Cheung TS, et al. Apoptosis in mesenchymal stromal cells induces in vivo recipient-mediated immunomodulation. Sci Transl Med 2017;9:eaam7828.
38. Kiani AA, Kazemi A, Halabian R, Mohammadipour M, Jahanian-Najafabadi A, Roudkenar MH. HIF-1α confers resistance to induced stress in bone marrow-derived mesenchymal stem cells. Arch Med Res 2013;44:185-93.
39. Sharma RR, Pollock K, Hubel A, McKenna D. Mesenchymal stem or stromal cells: a review of clinical applications and manufacturing practices. Transfusion 2014;54:1418-37.
40. Cornelissen AS, Maijenburg MW, Nolte MA, Voermans C. Organ-specific migration of mesenchymal stromal cells: Who, when, where and why? Immunol Lett 2015;168:159-69.
41. Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008;371:1579-86.
42. Ullah M, Liu DD, Thakor AS. Mesenchymal stromal cell homing: mechanisms and strategies for improvement. Iscience 2019;15:421-38.
43. Rizk M, Monaghan M, Shorr R, Kekre N, Bredeson CN, Allan DS. Heterogeneity in studies of mesenchymal stromal cells to treat or prevent graft-versus-host disease: a scoping review of the evidence. Biol Blood Marrow Transplant 2016;22:1416-23.
44. Resnick IB, Barkats C, Shapira MY, Stepensky P, Bloom AI, Shimoni A, et al. Treatment of severe steroid resistant acute GVHD with mesenchymal stromal cells (MSC). Am J Blood Res 2013;3:225-38.
45. Ball LM, Bernardo ME, Roelofs H, van Tol MJ, Contoli B, Zwaginga JJ, et al. Multiple infusions of mesenchymal stromal cells induce sustained remission in children with steroid‐refractory, grade III–IV acute graft‐versus‐host disease. Br J Haematol 2013;163:501-9.
46. Kurtzberg J, Prockop S, Teira P, Bittencourt H, Lewis V, Chan KW, et al. Allogeneic human mesenchymal stem cell therapy (remestemcel-L, Prochymal) as a rescue agent for severe refractory acute graft-versus-host disease in pediatric patients. Biol Blood Marrow Transplant 2014;20:229-35.
47. Introna M, Lucchini G, Dander E, Galimberti S, Rovelli A, Balduzzi A, et al. Treatment of graft versus host disease with mesenchymal stromal cells: a phase I study on 40 adult and pediatric patients. Biol Blood Marrow Transplant 2014;20:375-81.
48. Zhao K, Lou R, Huang F, Peng Y, Jiang Z, Huang K, et al. Immunomodulation effects of mesenchymal stromal cells on acute graft-versus-host disease after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2015;21:97-104.
49. Kuçi Z, Bönig H, Kreyenberg H, Bunos M, Jauch A, Janssen JW, et al. Mesenchymal stromal cells from pooled mononuclear cells of multiple bone marrow donors as rescue therapy in pediatric severe steroid-refractory graft-versus-host disease: a multicenter survey. Haematologica 2016;101:985-94.
50. Muroi K, Miyamura K, Okada M, Yamashita T, Murata M, Ishikawa T, et al. Bone marrow-derived mesenchymal stem cells (JR-031) for steroid-refractory grade III or IV acute graft-versus-host disease: a phase II/III study. Int J Hematol 2016;103:243-50.
51. Dotoli G, De Santis G, Orellana M, de Lima Prata K, Caruso S, Fernandes T, et al. Mesenchymal stromal cell infusion to treat steroid-refractory acute GvHD III/IV after hematopoietic stem cell transplantation. Bone Marrow Transplant 2017;52:859-62
52. Česen Mazič M, Girandon L, Kneževič M, Avčin SL, Jazbec J. Treatment of severe steroid-refractory acute-graft-vs.-host disease with mesenchymal stem cells–single center experience. Front B ioeng Biotechnol 2018;6:93.
53. Döring M, Cabanillas Stanchi KM, Lenglinger K, Treuner C, Gieseke F, Erbacher A, et al. Long-term follow-up after the application of mesenchymal stromal cells in children and adolescents with steroid-refractory graft-versus-host disease. Stem Cells Dev 2021;30:234-46.
54. Zhao K, Lin R, Fan Z, Chen X, Wang Y, Huang F, et al. Mesenchymal stromal cells plus basiliximab, calcineurin inhibitor as treatment of steroid-resistant acute graft-versus-host disease: a multicenter, randomized, phase 3, open-label trial. J Hematol Oncol 2022;15:22.
55. Macías-Sánchez MdM, Morata-Tarifa C, Cuende N, Cardesa-Gil A, Cuesta-Casas MÁ, Pascual-Cascon MJ, et al. Mesenchymal stromal cells for treating steroid-resistant acute and chronic graft versus host disease: A multicenter compassionate use experience. Stem Cells Transl Med 2022;11:343-55.
56. Chen X, Wang C, Yin J, Xu J, Wei J, Zhang Y. Efficacy of mesenchymal stem cell therapy for steroid-refractory acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis. PLoS One 2015;10:e0136991.
57. Hashmi S, Ahmed M, Murad MH, Litzow MR, Adams RH, Ball LM, et al. Survival after mesenchymal stromal cell therapy in steroid-refractory acute graft-versus-host disease: systematic review and meta-analysis. Lancet Haematol 2016;3:e45-e52.
58. Lin T, Yang Y, Chen X. A review of the application of mesenchymal stem cells in the field of hematopoietic stem cell transplantation. Eur J Med Res 2023;28:268.
59. Erbey F, Atay D, Akcay A, Ovali E, Ozturk G. Mesenchymal stem cell treatment for steroid refractory graft-versus-host disease in children: a pilot and first study from Türkiye. Stem Cells Int 2016;2016:1641402.
60. Keklik M, Deveci B, Celik S, Deniz K, Gonen ZB, Zararsiz G, et al. Safety and efficacy of mesenchymal stromal cell therapy for multi-drug-resistant acute and late-acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. Ann Hematol 2023;102:1537-47.
61. Salmenniemi U, Itälä-Remes M, Nystedt J, Putkonen M, Niittyvuopio R, Vettenranta K, et al. Good responses but high TRM in adult patients after MSC therapy for GvHD. Bone Marrow Transplant 2017;52:606-8.
62. Zhou X, Jin N, Wang F, Chen B. Mesenchymal stem cells: a promising way in therapies of graft-versus-host disease. Cancer Cell Int 2020;20:114.
63. Stoma I, Karpov I, Krivenko S, Iskrov I, Milanovich N, Koritko A, et al. Mesenchymal stem cells transplantation in hematological patients with acute graft-versus-host disease: characteristics and risk factors for infectious complications. Ann Hematol 2018;97:885-91.
64. Herberts CA, Kwa MS, Hermsen HP. Risk factors in the development of stem cell therapy. J Transl Med 2011;9:1-14.
65. Volarevic V, Nurkovic J, Arsenijevic N, Stojkovic M. Concise review: therapeutic potential of mesenchymal stem cells for the treatment of acute liver failure and cirrhosis. Stem Cells 2014;32:2818-23.